AdvanCell Isotopes Pty Ltd

Atley SolutionsBiotechnologySweden

67% match

Atley Solutions is a global leader in commercial products and services for astatine-related (At-211) radiopharmaceutical development and scalable manufacturing, originating from research at the University of Gothenburg.

AcroCyte TherapeuticsBiotechnologyUnited States

62% match

AcroCyte Therapeutics, Inc. is a biotechnology company dedicated to overcoming common laboratory challenges through its proprietary R³CE rapid, reproducible, rare cell 3D expansion technology. Recognized with awards such as the Taiwan National Innovation Award, the company focuses on advancing biomedical research and cell-based applications.

THOR MEDICALTRMED · PharmaceuticalsNorway

73% matchPublic

Thor Medical produces and supplies alpha-particle emitters used in targeted cancer therapy and radionuclide treatments. The company utilizes a proprietary, environmentally friendly technology to extract radioactive decay products from thorium for medical applications.

FluicellFLUI · Health CareSweden

61% matchPublic

Fluicell develops precision-engineered biological tissues and single-cell bioprinting technologies for regenerative medicine and drug screening. Using its proprietary platforms, including Nexocyte and Biopixlar, the company creates transplantable tissues to target diseases such as type 1 diabetes and provides advanced tools and screening models for pharmaceutical and academic partners.

API Co supplies active pharmaceutical ingredients, intermediates, excipients, and nutraceuticals for the healthcare industry.

Radiopharm Theranostics LtdRADX · BiotechCarlton, Australia

73% matchPublic

Radiopharm Theranostics Limited, an Australian company established in Carlton in 2021, specializes in the research and development of cutting-edge radiopharmaceutical treatments. Their mission is to address critical gaps in healthcare by creating products for both diagnostic imaging and therapeutic intervention across a spectrum of challenging medical conditions. The company's diverse pipeline features: RAD 204, designed to target PD-L1 for non-small cell lung cancer; RAD 202, aimed at HER2 for breast cancer and other solid tumor types; and two avß6 integrin-targeting agents, RAD 301 (a diagnostic tool for pancreatic ductal adenocarcinoma) and RAD 302 (a therapeutic agent for various cancers). Other significant developments include RAD 101 and RAD 102 for brain metastases, RAD 402 for advanced prostate cancer, and RV01 for multiple solid tumors. To accelerate the clinical progression of its radiopharmaceutical assets, Radiopharm Theranostics maintains a strategic partnership with Lantheus Holdings, Inc.